Paint Therapeutics is an emerging seed-funded biotechnology company utilizing its proprietary drug targeting algorithm to improve localization and duration of action of therapeutic agents in the tissues where they are needed most. Paint’s conjugation-based therapeutic development platforms enable rapid generation of clinical lead compounds with new compositions of matter starting from drugs already known to be active. Our most advanced platform, PulmoPaint™, targets diseases of the lungs, and our lead program for treatment of inflammatory lung diseases is on track for IND in 2025. We are advancing an extensive pipeline of additional PulmoPaint™ products including immune potentiating approaches for lung-resident cancers, treatments for refractory and resistant bacterial lung infections including NTM, and preventive agents for viral respiratory infection prophylaxis. Paint Tx is seeking additional funding partners to continue both lead advancement and further platform development.
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://paintherapeutics.com
- Keywords
- Pittsburgh.
Paint Therapeutics Questions
Paint Therapeutics's website is http://paintherapeutics.com
Paint Therapeutics's LinkedIn profile is https://www.linkedin.com/company/paint-therapeutics
Paint Therapeutics has
3 employees.
View email and phone details for 3
employees at Paint Therapeutics.
Paint Therapeutics's industry is
Biotechnology Research
Paint Therapeutics's top competitors are
Paint Therapy By Vartika,
Thomas Financial Group,
Trunorth Advisors,
Soleil Therapeutics,
Pathovax Llc,
Radyus Research,
Xcalibyte,
Corporate Connections At Pitt Business,
Jgh Consulting,
Omega Bioservices.
Paint Therapeutics's categories are Biotechnology Research
Paint Therapeutics's founding year is 2022
